Placebo + RO5285119
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder
Trial Timeline
Nov 21, 2016 → Jun 30, 2020
NCT ID
NCT02901431About Placebo + RO5285119
Placebo + RO5285119 is a phase 2 stage product being developed by Roche for Autism Spectrum Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT02901431. Target conditions include Autism Spectrum Disorder.
What happened to similar drugs?
0 of 10 similar drugs in Autism Spectrum Disorder were approved
Approved (0) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02901431 | Phase 2 | Terminated |
Competing Products
20 competing products in Autism Spectrum Disorder